

HEAD AND NECK DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

SUNDAY APRIL 27TH, 2025, 10:00 AM – 1:00 PM

CO-CHAIRS : JOHN HILTON AND SCOTT BRATMAN
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical trial and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.
- To identify mentoring opportunities for new investigators.

10:00 am Welcome

10:05 am Proposals

Chemo-pembrolizumab & eftilagimod aLpha In CPS<20% recurrent/metastatic caNCer of the Head and Neck (BRILLIANCE-HN)

A. Kartolo

ctDNA kinetics to guide treatment in patients treated with immunotherapy in recurrent metastatic head and neck cancer

E. Sanz Garcia

ctDNA kinetics to guide treatment in patients treated with definitive radiotherapy

S. Bratman

NRG HN2405: A Phase II randomized trial of neoadjuvant chemotherapy or chemoimmunotherapy in patients with recurrent/persistent PD-L1 enriched SCCHN undergoing salvage therapy

J. Hilton

A Pragmatic Randomized Trial Comparing Weekly Docetaxel to Cisplatin in Patients with Locally Advanced Head & Neck Cancer Treated with Radiation

E. Winquist

11:25 am Break



| | | |
|-----------------|--|----------------------|
| 11:40 am | <u>Relevant Updates from Non-CCTG Trials</u> | |
| | Stereotactic boost and SH ort-course Radiation Therapy for HPV-aOroPharynx Cancer (S2HORT-OPC) Trial: A Randomized Phase III Trial | H. Bahig |
| 11:50 am | <u>Update On Approved Not Activated Trials</u> | |
| | HN.14 - A Randomized Phase II Trial of Delayed, Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with Low Risk HPV Related Oropharynx Cancer | A. McPartlin |
| 12:00 pm | <u>Update on Recently Activated Trials</u> | |
| | SKC.1/NRG HN014 - Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-adjusted Treatment versus Standard-of-Care (SOC) Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | T. Petrella |
| | HN.13 - Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study) | I. Poon |
| 12:20 pm | <u>Update on Open Trials</u> | |
| | HN.11 - SPECT-CT Guided ELE ctive Con tralateral Neck Treatment in Lateralized Oropharynx Cancer (SELE CT): For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial | J. de Almeida |
| | HN.10 - A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma | S. Bratman |
| | HN.9 - Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) | A. Spreafico |
| | PM.2 - Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO) | A. Spreafico |
| 12:40 pm | <u>Head and Neck Committee Representation</u> | |
| | <ul style="list-style-type: none"> - Executive Committee - Practicum Program - NCI Task Force Representation | |
| 12:50 pm | <u>Vision Leadership Program</u> | A. Spreafico |
| 1:00 pm | Meeting Adjourned | |

